MF59 + eTIV + H5N1 (Novartis)

MF59 + eTIV + H5N1 is an investigational tetravalent influenza vaccine developed by Novartis Vaccines. It combines a seasonal egg-derived trivalent influenza vaccine (eTIV) with a pandemic H5N1 influenza antigen, formulated with the MF59 adjuvant. MF59 is a squalene-based oil-in-water emulsion that enhances the immune response by promoting the recruitment of antigen-presenting cells and stimulating local cytokine production. The vaccine is designed to provide simultaneous protection against three seasonal influenza strains and one pandemic-potential H5N1 strain in a single intramuscular injection. This approach aims to simplify vaccination logistics and improve population readiness during a potential avian influenza pandemic. Clinical development reached Phase II, where it was evaluated for safety and immunogenicity compared to separate administrations of seasonal and pandemic vaccines.

Other names

Novartis Tetravalent Influenza Vaccine (H5N1)MF59-adjuvanted H5N1-seasonal influenza vaccineMF-59-adjuvanted H5N1-seasonal influenza vaccineMF 59-adjuvanted H5N1-seasonal influenza vaccine